Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 1, 2017 19:24:18 GMT -5
u1682002 as I have pointed out previously, ZGNX survival a reverse followed by dilution. It provided the $ to conduct phase 3 trials of fenfluramine for Dravet syndrome which are nearly complete.
|
|
|
Post by sayhey24 on Feb 1, 2017 19:51:38 GMT -5
look- at least they are covered now. This is insurance. Yes there is a fair chance they will need to take out that insurance. But at least they have some time to either nail down a deal or grow scripts before they hit the point where they are forced to pull this lever. It was the most sensible thing for them to do at this stage. Now Mike better get scripts, or Ray better get Epi or some trials started. $2 billion and over a decade later still under 300 scripts/week. Afrezza has been ours for 6 months. Statistically negligible results in that time frame on the scale we need. How much time do they need? How much more money? Is that money even available? They are in over their heads and it's never been more clear than today. They may have a plan, but it doesn't appear that plan has been working. I'm not confident they'll figure it out. It's important to get packaging correct. It's important to get payors on board. We've increased coverage but have seen no growth in script counts. The biggest issue isn't with coverage. I don't think the biggest issue is packaging, either, although I guess we'll see. In my eyes the biggest issue is either getting an audience with a physician to educate them on Afrezza, or pure apathy from a prescriber's standpoint if that meeting ever occurred. This thing was bungled from the get go, but you only get one chance to make a first impression. I hope for our sakes there are still enough doctors out there who have not had a bad experience with Afrezza to recover. Unless the doctor understands what they are being handed with afrezza I would think most would have had a bad experience. Do most of these doctors even have a baseline of what a patience's pre-prandail and post-prandail BGs are prior to giving the PWD afrezza? If not, why even bother. Before a patient is even given afrezza, that doctor should have 2 solid weeks of BG level results and a log of the foods being eaten which generated those numbers. Then they can send the patient away with the 4u, 8u and 12u. Just think how crazy this titration pack is. They are sending the patient out in the dark and telling them experiment with something unlike anything they have used. Are they even using CGMs? If not its a lot of finger pricks to do the type of measuring to properly titrate. You would think by now MNKD would have a computer model to plug in the CGM values for minimally 2 weeks with accompanying meals/carbs and that model should be able to suggest an initial dosing schedule. Will it need tweeking, absolutely but its a starting point. Send these PWD off for 2 weeks with a Libre. Schedule their spirometry and have them come back in 2 weeks and then download the Libre data and print the initial schedule. Then they can write the script.
|
|
|
Post by james on Feb 1, 2017 20:01:20 GMT -5
The split is only step one. Step two is the dilution later this year to raise another $50M+ to keep operations running. This is the obvious and unavoidable path. James, do you know any cases that an investors got rewarded in the end after such a R/S? Thanks Personally, no. Search 'successful reverse stock splits' and you'll see that there are plenty of cases were companies succeed and investors are rewarded afterwards. As others point out, it's not the reverse split that is the issue. It's irrelevant from a valuation and investor benefits standpoint. What's relevant is that the company will almost certainly dilute shareholder ownership to raise operating cash during the year and this is yet another signal that it is coming.
|
|